In human prostate tumor samples taken before ADT, the density of perivascular FR-β+ CD68+ TAMs was significantly greater in patients who did not respond to ADT than in responders; there was also a nonsignificant trend for PV FR-β+ CD68+ TAMs to also be greater after ADT in nonresponders than in responders [174]. This evidence concerns the gene CD68 and prostate neoplasm.